Sign in
WithdrawnNo phase

Feasibility Study of Patients With Severe MR Treated With the Cardiovalve TMVR System

Key facts

Who runs it
Cardiovalve Ltd.
Where
Greece and Poland2 sites in 2 countriesChoose a country to see its sites
Trial code
Status
Withdrawn
Started
Sept 2019
Ended
15 Dec 2023
Type of study
Interventional
Treatments tested
  • Implantation
Record updated
7 May 2026
Why it stopped
Amended and merged with AHEAD-EU study

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 36 criteriaShow less

Who cannot take part

  • Prior stroke or TIA within 3 months or Modified Rankin Scale ≥4 disability
  • Acute myocardial infarction within the previous 30 days
  • Any prior heart valve surgery or transcatheter mitral intervention
  • Any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days
  • Rheumatic heart disease or endocarditis within the previous 3 months
  • CRT/ICD implant within 30 days Anatomical Exclusion Criteria (assessed by pre-procedural imaging)
  • Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing heart failure other than dilated cardiomyopathy of either ischemic or non-ischemic etiology
  • Untreated clinically significant coronary artery disease requiring revascularization
  • Tricuspid valve disease requiring surgery or severe tricuspid regurgitation
  • Aortic or pulmonic valve disease requiring surgery
  • Severe tricuspid or aortic valve disease; General Exclusion Criteria
  • Hemodynamic instability defined as systolic pressure < 90mmHg or the need for inotropic support or intra-aortic balloon pump or other hemodynamic support device, or any mechanical heart assistance
  • Subject has contrast agent hypersensitivity that cannot be adequately pre-medicated, has an allergy to Nitinol alloys (nickel and titanium), or has intolerance to antiplatelet, anticoagulant, or thrombolytic medications
  • Bleeding diathesis or hypercoagulable state
  • Active peptic ulcer or active gastrointestinal bleeding
  • Need for emergent or urgent surgery for any reason or any planned cardiac Surgery within the next 12 months
  • Subject with hepatic insufficiency
  • Subject has a co-morbid illness that may result in a life expectancy of less than one year
  • Active infection that requires antibiotic therapy
  • Left Ventricular Ejection Fraction (LVEF) <30%
  • Patients with renal insufficiency (creatinine > 2.5 mg/dL)
  • Cardiovascular Exclusion Criteria
  • Existence of inferior vena cava filter or atrial septal device (contraindicating femoral access and transseptal catheterization)
  • LV end diastolic diameter > 70mm
  • Significant abnormalities of the mitral valve and sub-valvular apparatus
  • Severe mitral annular or leaflets calcification
  • Left atrial or LV thrombus or vegetation
  • Severe right ventricular dysfunction
  • Subject who is currently participating in an investigational study, other than this study
  • Pulmonary artery systolic pressure >70 mmHg
  • Subject is pregnant, breastfeeding or intend to become pregnant within one year

Other criteria

  • General Inclusion Criteria:
  • NYHA functional II, III or ambulatory IV 3. Severe mitral regurgitation (MR grade 3-4+) with pronounced secondary MR etiology 4. Subject is on optimal guideline-directed medical therapy for heart failure for at least 30 days or CRT if indicated
  • Elevated risk for conventional open mitral valve repair or replacement surgery in the consideration of the site Heart Team (including a cardiac surgeon, a cardiologist and imaging specialist as a minimum) based on STS/Euro Score II (per MVARC Part 1), frailty and co-morbidities
  • Able to undergo Transesophageal Echocardiography (TEE). 7. Subject understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed
  • The subject commits to return for the scheduled post-operative follow-up visits at the hospital; Anatomical Inclusion Criteria 9. Suitable for femoral access procedure and trans septal catheterization 10. Native mitral valve geometry and size and LV outflow tract characteristics compatible with the Cardiovalve (as assessed by the independent Screening Committee)

This trial has no sites in United States.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study will test the safety and performance of the Cardiovalve transfemoral mitral valve replacement system in treating patients with severe mitral regurgitation who are at high risk for open chest surgery. The system is comprised of comprised of: 1) an Implant; 2) a Delivery System (DS); and 3) Accessories that are required for the implantation procedure. the procedure is performed under general anesthesia.

The group in the trial

  • ImplantationTreatment being tested

    Eligible patients will undergo implantation with the Cardiovalve system

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Feasibility Study of High Surgical Risk Patients With Severe Mitral Regurgitation Treated With the Cardiovalve Transfemoral Mitral Valve System
Record updated
7 May 2026